Management of patients with chronic renal insufficiency in the Northeastern United States.
暂无分享,去创建一个
A. Kausz | B. Pereira | R. Ruthazer | S. Khan | R. Abichandani | W. Kazmi | G. Obrador | Samina S. Khan | S. Khan | S. Khan | S. Khan
[1] B. Pereira,et al. Optimization of pre-ESRD care: the key to improved dialysis outcomes. , 2000, Kidney international.
[2] M. Drezner,et al. Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. , 1985, Kidney international.
[3] A. Kausz,et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. , 1999, Journal of the American Society of Nephrology : JASN.
[4] R. Chesney,et al. Morbidity and Mortality of Renal Dialysis: An NIH Consensus Conference Statement , 1994, Annals of Internal Medicine.
[5] T. Greene,et al. Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.
[6] J. Bergström. Nutrition and mortality in hemodialysis. , 1995, Journal of the American Society of Nephrology : JASN.
[7] The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.
[8] A. Levey,et al. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. , 1997, Annals of internal medicine.
[9] B. Pereira,et al. Hematocrit Level Associated Mortality in Hemodialysis Patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610–619, 1999 , 2000, Seminars in dialysis.
[10] G. Beck,et al. The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .
[11] F. Port,et al. Morbidity and mortality in dialysis patients. , 1994, Kidney international.
[12] S. Greenfield,et al. Recent developments and future issues in the use of health status assessment measures in clinical settings. , 1992, Medical care.
[13] R. Saracho,et al. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[15] J. Singer,et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] J. Assal,et al. [Long-term complications in diabetes mellitus]. , 1989, Acta medica portuguesa.
[17] A. Collins,et al. Hematocrit level and associated mortality in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[18] David C. Murray,et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] C. Schmid,et al. Comorbidity Assessment in Hemodialysis and Peritoneal Dialysis Using the Index of Coexistent Disease , 2000, Seminars in dialysis.
[20] P. Ratcliffe,et al. Late referral for maintenance dialysis. , 1984, British medical journal.
[21] G. Beck,et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.
[22] J. Sondheimer,et al. An analysis of the adequacy of preparation for end-stage renal disease care in Michigan. Michigan Renal Plan Task Force. , 1995, ASAIO journal.
[23] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[24] W. Keane,et al. Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[25] T. Shoji,et al. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. , 1997, Kidney international. Supplement.
[26] S. Schwab,et al. Assessing the adequacy of vascular access and its relationship to patient outcome. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] M. Rocco,et al. The costs of hospitalizations due to hemodialysis access management. , 1995, Nephrology news & issues.
[28] S. Klahr. The modification of diet in renal disease study. , 1989, The New England journal of medicine.
[29] R. Rettig. The social contract and the treatment of permanent kidney failure. , 1996, JAMA.
[30] J. McGill,et al. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. , 1995, The American journal of medicine.
[31] A. Levin,et al. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[33] B. Kasiske,et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[34] A. Kausz,et al. Hospital utilization among chronic dialysis patients. , 2000, Journal of the American Society of Nephrology : JASN.
[35] E. Ritz,et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. , 1994, Journal of the American Society of Nephrology : JASN.
[36] J. Adamson,et al. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin. , 1990, Contributions to nephrology.
[37] H. Lebovitz,et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. , 1994, Kidney international. Supplement.
[38] A. Collins,et al. Hematocrit levels and hospitalization risks in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[39] A. Kausz,et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. , 1999, Journal of the American Society of Nephrology : JASN.
[40] E G Lowrie,et al. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] S. Colagiuri,et al. The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.
[42] J. Coresh,et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] R. Parker,et al. Spontaneous dietary protein intake during progression of chronic renal failure. , 1995, Journal of the American Society of Nephrology : JASN.
[44] W. McClellan,et al. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[45] D. McKusick,et al. The next ten years of health spending: what does the future hold? The Health Expenditures Projection Team. , 1998, Health affairs.